ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright Bioconnect Conference on January 10, 2022. The conference will be held virtually from January 10 to January 13, 2022.
For more information, please refer to the press release.